Logo image of GRAY

GRAYBUG VISION INC (GRAY) Stock Fundamental Analysis

NASDAQ:GRAY - Nasdaq - US38942Q1031 - Common Stock - Currency: USD

5.5  -0.67 (-10.8%)

After market: 6.51 +1.01 (+18.36%)

Fundamental Rating

2

Taking everything into account, GRAY scores 2 out of 10 in our fundamental rating. GRAY was compared to 193 industry peers in the Pharmaceuticals industry. While GRAY has a great health rating, there are worries on its profitability. GRAY has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GRAY had negative earnings in the past year.
In the past year GRAY has reported a negative cash flow from operations.
In the past 5 years GRAY always reported negative net income.
GRAY had a negative operating cash flow in each of the past 5 years.
GRAY Yearly Net Income VS EBIT VS OCF VS FCFGRAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

GRAY has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GRAY Yearly ROA, ROE, ROICGRAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

GRAY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRAY Yearly Profit, Operating, Gross MarginsGRAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for GRAY has been increased compared to 1 year ago.
GRAY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GRAY Yearly Shares OutstandingGRAY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 5M 10M 15M 20M
GRAY Yearly Total Debt VS Total AssetsGRAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

GRAY has an Altman-Z score of -8.80. This is a bad value and indicates that GRAY is not financially healthy and even has some risk of bankruptcy.
GRAY's Altman-Z score of -8.80 is on the low side compared to the rest of the industry. GRAY is outperformed by 76.92% of its industry peers.
GRAY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.8
ROIC/WACCN/A
WACCN/A
GRAY Yearly LT Debt VS Equity VS FCFGRAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 20M -20M 40M 60M 80M

2.3 Liquidity

GRAY has a Current Ratio of 10.72. This indicates that GRAY is financially healthy and has no problem in meeting its short term obligations.
GRAY has a better Current ratio (10.72) than 83.71% of its industry peers.
A Quick Ratio of 10.72 indicates that GRAY has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 10.72, GRAY belongs to the best of the industry, outperforming 83.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.72
Quick Ratio 10.72
GRAY Yearly Current Assets VS Current LiabilitesGRAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

GRAY shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.70%.
EPS 1Y (TTM)1.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GRAY will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.89% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y5.14%
EPS Next 2Y13.89%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRAY Yearly Revenue VS EstimatesGRAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
GRAY Yearly EPS VS EstimatesGRAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GRAY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GRAY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRAY Price Earnings VS Forward Price EarningsGRAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRAY Per share dataGRAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 -100 200 -200 300

4.3 Compensation for Growth

A more expensive valuation may be justified as GRAY's earnings are expected to grow with 13.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.89%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

GRAY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GRAYBUG VISION INC

NASDAQ:GRAY (3/20/2023, 8:12:53 PM)

After market: 6.51 +1.01 (+18.36%)

5.5

-0.67 (-10.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-09 2023-03-09
Earnings (Next)05-08 2023-05-08
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners146.19%
Ins Owner Change0%
Market Cap617.26K
Analysts43.33
Price Target42.84 (678.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.5%
Min EPS beat(2)-2.5%
Max EPS beat(2)-2.5%
EPS beat(4)1
Avg EPS beat(4)-6.08%
Min EPS beat(4)-23.06%
Max EPS beat(4)7.33%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1100%
PT rev (3m)1100%
EPS NQ rev (1m)-58.7%
EPS NQ rev (3m)-58.7%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.02
P/tB 0.02
EV/EBITDA N/A
EPS(TTM)-1.66
EYN/A
EPS(NY)-1.69
Fwd EYN/A
FCF(TTM)-206.6
FCFYN/A
OCF(TTM)-203.86
OCFYN/A
SpS0
BVpS320.51
TBVpS320.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 91.12%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.72
Quick Ratio 10.72
Altman-Z -8.8
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)146.72%
Cap/Depr(5y)290.92%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.81%
EPS Next Y5.14%
EPS Next 2Y13.89%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.37%
OCF growth 3YN/A
OCF growth 5YN/A